

MSC 7844, Bethesda, MD 20892, (301) 435-2212, josephru@csr.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Bioengineering Research Partnerships—Biomedical Sensing.

*Date:* October 27, 2005.

*Time:* 1 p.m. to 2 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Pushpa Tandon, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5104, MSC 7854, Bethesda, MD 20892, (301) 435-2397, tandonp@csr.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, RIBT Member Conflicts.

*Date:* October 27, 2005.

*Time:* 1 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* George M. Barnas, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health 6701 Rockledge Drive, Room 2180, MSC 7818, Bethesda, MD 20892, (301) 435-0696, barnasg@csr.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Nuclear Membrane Proteins.

*Date:* October 27, 2005.

*Time:* 2 PM to 3 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health; 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Jonathan Arias, PHD, Scientific Review Administrator, National Institutes of Health, 6701 Rockledge Drive, Room 5170 MSC 7840, Bethesda, MD 20892, 301-435-2406, ariasj@csr.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Approaches in Cancer Therapeutics.

*Date:* October 27, 2005.

*Time:* 3 PM to 5 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Joanna M. Watson, PHD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6046-G, MSC 7804, Bethesda, MD 20892, 301-435-1048, watsonjo@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: September 30, 2005.

**Anthony M. Coelho, Jr.**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-20254 Filed 10-6-05; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: North-2'-Deoxy-Methanocarbothymidines as Antiviral Agents Against Poxvirus

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive license to practice the following invention as embodied in the following patent applications: HHS Ref. No. E-047-2005; U.S. Provisional Patent Application Number 60/684,811, filed on May 25, 2005 to N&N Scientific, having a place of business in Maryland but incorporated in Illinois. The patent rights in these inventions have been assigned to the United States of America.

**DATES:** Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before December 6, 2005 will be considered.

**ADDRESSES:** Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Robert M. Joynes, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; E-mail: joynesr@od.nih.gov; Telephone: (301) 594-6565; Facsimile: (301) 402-0220.

**SUPPLEMENTARY INFORMATION:** The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. The field of use may be limited to the treatment of poxviruses.

The subject invention relates to a method for the prevention or treatment of poxvirus infection by administering an effective amount of an antiviral agent comprising a carbocyclic 2'-deoxynucleoside analog (as described in U.S. Patent Nos. 5,629,454 and 5,869,666) to an individual in need thereof. North-methanocarbothymidine (N-MCT), a thymidine analog with a pseudosugar moiety locked in the northern conformation, which was previously shown to exert strong activity against herpes simplex virus types 1 and 2, has been identified as exhibiting potent activity against poxviruses. N-MCT effectively blocks poxvirus synthesis through its phosphorylated metabolite, which is more efficiently produced in poxvirus-infected cells. This compound is approximately seven times more potent than cidofovir against vaccinia and cowpox in cell culture. The higher potency and target specificity of N-MCT against poxvirus, as well as its high margin of safety, makes it a highly desirable agent against the poxviridae family. In addition, the mechanism of N-MCT may be different from that of cidofovir, making it even more desirable due to the scarcity of the potential available efficacious anti-pox agents currently under development.

The licensed territory will be exclusive worldwide.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: September 27, 2005.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 05-20242 Filed 10-6-05; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOMELAND SECURITY

### Office of the Secretary

#### Senior Executive Service Performance Review Board

**AGENCY:** Office of the Secretary, DHS.

**ACTION:** Notice.

**SUMMARY:** This notice announces the appointment of the members of the Senior Executive Service Performance

Review Boards for the Department of Homeland Security. The purpose of the Performance Review Board is to review and make recommendations concerning proposed performance appraisals, ratings, bonuses, pay adjustments, and other appropriate personnel actions for incumbents of Senior Executive Service positions of the Department.

**EFFECTIVE DATES:** This Notice is effective October 7, 2005.

**FOR FURTHER INFORMATION CONTACT:**

Carmen Arrowood, Office of the Chief Human Capital Office, telephone (202) 357-8348.

**SUPPLEMENTARY INFORMATION:** Each Federal agency is required to establish one or more performance review boards (PRB) to make recommendations, as necessary, in regard to the performance of senior executives within the agency. 5 U.S.C. 4314(c). This notice announces the appointment of the members of the PRB for the Department of Homeland Security (DHS). The purpose of the PRB is to review and make recommendations concerning proposed performance appraisals, ratings, bonuses, pay adjustments, and other appropriate personnel actions for incumbents of SES positions within DHS.

The Board shall consist of at least three members. In the case of an appraisal of a career appointee, more than half of the members shall consist of career appointees. Composition of the specific PRBs will be determined on an ad hoc basis from among the individuals listed below:

Adamoli, Joseph B.  
Adams, Audrey L.  
Aguilar, David V.  
Ahern, Jayson P.  
Alexander, Jane A.  
Arcos, Cresencio  
Balaban, Richard L.  
Bathurst, Donald G.  
Beardsworth, Richard  
Bergman, Cynthia L.  
Besanceney, Brian R.  
Blair, James D.  
Bone, Craig, E. RADML  
Boudreaux, Chad  
Boyd, David G.  
Brice-O'Hara, Sally RADM  
Broderick, Matthew E.  
Buikema, Edward G.  
Cannatti, Ashley  
Charbo, Lawrence Scott  
Cira, Anthony Thomas  
Cuddihy, Joseph D.  
Currier, John P. RADML  
DiGregorio, Elizabeth L.  
Dinanno, Thomas G.  
Dolan, Kay Frances  
Dooher, John C.  
Duke, Elaine C.  
Dunham, Carol A.

Dunlap, James L.  
Fagerholm, Eric N.  
Filler, Joshua D.  
Forman, Marcy M.  
Fonash, Peter M.  
Hale, Janet  
Hall, Michael J.  
Hasting, Charles R.  
Hastings, Scott O.  
Hill, Kenneth  
Holcomb, Lee B.  
Irving, Paul D.  
James, Ronald J.  
Jones, Rendell L.  
Kelleher, John J.  
Kent, Donald H.  
Khatri, Prakash I.  
Kubricky, John J.  
Kunkel, David W. RADM  
Ladd, Paul E.  
Lang, Gary J.  
Langlois, Joseph E.  
Lederer, Calvin M.  
Lockwood, Thomas  
Lumsden, Sheila  
Lynch, Dennis F.  
MacDonald, John R.  
Mandelker, Sigal P.  
Maner, Andrew B.  
Martinez-Fonts, Alfonso  
Matticks, John  
Maurstad, David I.  
Mayer, Matt A.  
McC Campbell, Christy  
McCarthy, Maureen I.  
McDonald, Sallie  
McKennis, Amy D.  
McNamara, John C.  
McQueary, Charles E.  
Mitchell, Andrew  
Mocny, Robert A.  
Nagel, Brian K.  
Nimmich, Joseph L. RDML  
O'Neill, James P.  
O'Reilly, Terrance M.  
Ostergaard, Daniel J.  
Oxford, Vayl S.  
Paar, Thomas C.  
Parent, Wayne  
Prewitt, Keith L.  
Prillaman, K. Gregg  
Quinn, Thomas  
Reyes, Juan  
Richmond, Susan  
Riggs, Barbara S.  
Robles, Alfonso  
Rogers, George D.  
Rossides, Gale D.  
Rothwell, Gregory D.  
Runge, Jeffrey W.  
Santana, Catherine Y.  
Schied, Eugene H.  
Schmitz, Michael T.  
Shingler, Wendell C.  
Sirois, R. Dennis RADM  
Smith, Robert M.  
Sposato, Janis A.  
Stalhschmidt, Patricia K.  
Stallworth, Charles E.

Stenger, Michael C.  
Stephan, Robert B.  
Stephens, Michael P.  
Sullivan, Daniel  
Sullivan, Mark J.  
Sutherland, Daniel W.  
Tambone, Victor J.  
Teufel, Hugo  
Thomson, E. Keith  
Torres, John  
Trissell, David A.  
Turner, Pamela J.  
Turner, Todd H.  
Vanacore, Michael J.  
Venuto, Kenneth T. RADM  
Vint, Norbert E.  
Walker, Carmen H.  
Weber, Robert W.  
West, Robert C.  
Whitehead, Joel R. RDML  
Whitford, Richard A.  
Wiggins, Michael  
Williams, Dwight  
Williams, James A.  
Williams, Richard N.  
Wood, John F.  
Woodson, Mary Ann

This notice does not constitute a significant regulatory action under section 3(f) of Executive Order 12866. Therefore, DHS has not submitted this notice to the Office of Management and Budget. Further, because this notice is a matter of agency organization, procedure and practice, DHS is not required to follow the rulemaking requirements under the Administrative Procedure Act (5 U.S.C. 553).

Dated: September 30, 2005.

**Rodney Markham,**

*Director, Executive Resources, Office of the Chief Human Capital Office.*

[FR Doc. 05-20167 Filed 10-6-05; 8:45 am]

**BILLING CODE 4410-10-P**

**DEPARTMENT OF HOMELAND SECURITY**

**Coast Guard**

**DEPARTMENT OF TRANSPORTATION**

**Maritime Administration**

[USCG-2005-22611]

**Neptune LNG, L.L.C., Liquefied Natural Gas Deepwater Port License Application**

**AGENCY:** Coast Guard, DHS; Maritime Administration, DOT.

**ACTION:** Notice of application.

**SUMMARY:** The Coast Guard and the Maritime Administration (MARAD) announce that they have received an application for the licensing of a